Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Sakamoto

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2023
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trialHisato Kawakami, Yu Sunakawa, Eisuke Inoue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2022
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE TrialTakayuki Yoshino, Eiji Oki, Toshihiro Misumi, et al.
Scientific Reports|March 9, 2026
RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational researchShonosuke Wakayama, Shin Takahashi, Kota Ouchi, et al.
Scientific Reports|April 10, 2026
Metabolic and functional pathways of gut microbiota in patients with gastric cancerRyo Matoba, Hiroshi Iijima, Yasuhiro Sakamoto, et al.
Journal of Gastrointestinal Oncology|May 18, 2023
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201Shin Takahashi, Kota Ouchi, Yasuhiro Sakamoto, et al.
Cancers|February 13, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Hiroya Taniguchi, Kay Uehara, Toshiaki Ishikawa, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2023
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trialHisato Kawakami, Yu Sunakawa, Eisuke Inoue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2022
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE TrialTakayuki Yoshino, Eiji Oki, Toshihiro Misumi, et al.
Scientific Reports|March 9, 2026
RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational researchShonosuke Wakayama, Shin Takahashi, Kota Ouchi, et al.
Scientific Reports|April 10, 2026
Metabolic and functional pathways of gut microbiota in patients with gastric cancerRyo Matoba, Hiroshi Iijima, Yasuhiro Sakamoto, et al.
Journal of Gastrointestinal Oncology|May 18, 2023
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201Shin Takahashi, Kota Ouchi, Yasuhiro Sakamoto, et al.
Cancers|February 13, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Hiroya Taniguchi, Kay Uehara, Toshiaki Ishikawa, et al.
Pageof 7